Published 22 April 2021 in Analysis
The Access to COVID-19 Tools (ACT) Accelerator (ACT-A) is a global collaboration launched in April 2020 to respond to the COVID-19 health crisis.
It brings together governments, scientists, firms, civil society, foundations, and international organizations.
The goal of the ACT-A is to accelerate development, equitable allocation, and scale-up delivery of COVID-19 vaccines, therapeutics, and diagnostics. By the end of 2021, the ACT-A aims to rapidly scale up the delivery of at least 2 billion doses of vaccines (to 20% of the population of 190 countries), 900 million diagnostic tests and 165 million treatment courses, and strengthen the health systems of 114 countries.
– > To know ACT-A’s funding needs to reach its objectives for 2021, see this article.
The Access to COVID-19 Tools (ACT) Accelerator is a time-limited global collaboration designed to rapidly leverage existing global public health infrastructure and expertise to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines, in order to expedite the end of the acute phase of the COVID-19 pandemic.
The ACT-A is convened by nine global health organizations, each bringing its own expertise to the table: research and development (CEPI, FIND, Wellcome Trust), market preparedness and access (Unitaid, FIND), control and norms setting (WHO), procurement (Global Fund, Gavi, Unitaid), support to health systems (World Bank, Global Fund, WHO).
The ACT Accelerator comprises four pillars: Diagnostics, Therapeutics and Vaccines (also known as COVAX), with the Health Systems Connector pillar working across the other three. Each pillar is managed by 2-3 partner agencies. Additionally, the WHO leads on the cross-cutting Access and Allocation workstream.
By early 2021, its goal is to secure 2 billion doses through the COVAX Facility, an actively managed portfolio of vaccine candidates across a broad range of technologies. All participating countries, regardless of income levels, will have equal access to these vaccines once they are developed. Read Gavi’s COVAX Facility governance explainer for more information.
Civil society and communities engagement are integrated in each of the pillars.